All In Biotech

Drug Trial Radar · NCT01110330

An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot

A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis

Last checked: Nov 19, 2026Latest source record: Apr 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 583 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

583

Actual

Start

Jul 2007

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo in treating patients with Tinea pedis, a skin infection commonly known as "athlete's foot" that is caused by a kind of mold called a fungus.

Conditions

  • Tinea Pedis

Interventions

  • Placebo creamDrug

    A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.

  • Ketoconazole 2% cream (formulation F012) (Nizoral)Drug

    A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.

  • Ketoconazole 2% cream (formulation F126)Drug

    A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Patients in the Positive Baseline Culture Set (PBCS) With Mycological Cure (MC) at Week 6Time frame: Week 6

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Bydgoszcz, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Torun, Poland

  • Site not named

    Cardiff, United Kingdom

  • Site not named

    Chorley, United Kingdom

  • Site not named

    Glasgow, United Kingdom

  • Site not named

    Liverpool, United Kingdom

  • Site not named

    Manchester, United Kingdom

  • Site not named

    Reading, United Kingdom

  • Site not named

    Sunbury-on-Thames, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.